Plain-English translation of NCT06594991 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three immunotherapy drugs—, , and —in people whose advanced melanoma has stopped responding to standard immunotherapy. The study wants to see if this three-drug approach is safe and effective, and whether it causes manageable side effects. This treatment is for people whose cancer has progressed despite previous immunotherapy.
Many patients with advanced melanoma stop responding to standard immunotherapy drugs over time. This trial explores whether combining three different immunotherapy drugs together might work for people whose cancer has become resistant to earlier treatments.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the three medications on a regular schedule: two drugs every three weeks and one drug every six weeks, given continuously throughout the study. You would attend regular clinic visits for treatment and to have your blood monitored and tumors measured with imaging scans. The study will track how well the treatment works, whether your cancer shrinks, and what side effects you experience.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States